Conference Day Three

We are currently developing the program for BioNetwork West 2012. As a courtesy, we're providing our most recent BioNetwork West Agenda.

Request an outline for the 2012 Agenda! Email us at bionetwork@wbresearch.com

7:30 Networking Breakfast & Conference Registration Sponsored By Sanofi

Networking Breakfast & Conference Registration Sponsored By Sanofi

8:45 Chairperson's Opening Remarks

Kiva Kolstein, Vice President, Head of Corporate New Business Development, Gerson Lehrman Group (GLG)
Doug Lichtman, Professor of Law, UCLA and Counsel Member, Gerson Lehrman Group (GLG)

Chairperson's Opening Remarks

Kiva Kolstein

Vice President, Head of Corporate New Business Development, Gerson Lehrman Group (GLG)

Kiva Kolstein is vice president, and global head of corporate new business development at Gerson Lehrman Group (GLG), where his team works with more than 175 corporations worldwide. In his 4 years at GLG, he has extensive experience partnering with executives in strategy and development, marketing, finance, pricing, reimbursement, research and development, and compliance. In his current role Kolst [read more]

Doug Lichtman

Professor of Law, UCLA and Counsel Member, Gerson Lehrman Group (GLG)

9:00 Panel: Licensing Promising Early-Stage Assets To Fill Gaps In Your Pipeline

Steven Ertel, Senior Vice President Corporate Developmemt, Acceleron Pharma Inc
Paul Eynott, Ph.D., Partnering & Innovation, US Head, Sanofi
James Schaeffer, Executive Director, Worldwide Licensing and External Research, MERCK
Alexander Schuth, Associate Director Business Development, Genentech, Inc.
Phil Tinmouth, Vice President, Business Development & Alliance Management, Vertex Pharmaceuticals Incorporated

Pharma is looking for early stage partnering opportunities to rebalance their pipelines for a long-term outlook that is deep and diversified. Many of the largest companies have business development groups dedicated to finding and investing in early stage technologies. The deal-making landscape is full of potential early stage technologies, so how will these early stage deals be structured to ensure a long term commitment? What mechanisms can biotechs build in to their business models to attract partnerships? This session will provide insights in to the strategies for early stage partnerships and deal structures.

Steven Ertel

Senior Vice President Corporate Developmemt, Acceleron Pharma Inc

Mr. Ertel joined Acceleron in January 2006 to lead the business development, market development, and investor/public relations functions. Mr. Ertel began his career in venture capital at Oxford Bioscience Partners and subsequently worked at several leading biotechnology companies including Genentech and Biogen Idec where he led project teams of preclinical and clinical stage programs, ran a market [read more]

Paul Eynott, Ph.D.

Partnering & Innovation, US Head, Sanofi

Paul Eynott, PhD, is Head of Partnering & Innovation, sanofi-aventis U.S. In this role, Paul is responsible for identifying external opportunities within the scope of “early-to-candidate”, working with both internal and external partners to ensure the integration of opportunities into the R&D portfolio. Prior to his new role as Head of Partnering & I [read more]

James Schaeffer

Executive Director, Worldwide Licensing and External Research, MERCK

Dr. Jim Schaeffer joined Merck Research Laboratories (MRL) in 1986. During his first 16 years at MRL, he directed research groups focusing primarily on neuroendocrine-related projects. Jim joined the Department of External Scientific Affairs in 2003 with primary responsibility for all neuroscience licensing opportunities and during the next 18 months, he was directly involved in the signing of fou [read more]

Alexander Schuth

Associate Director Business Development, Genentech, Inc.

Alex leads the partnering activities in the neuroscience field at Genentech. His team is responsible for screening scientific opportunities, leading due diligence and negotiating contract terms to access new therapies for neurological and psychiatric diseases. Transactions span across a broad spectrum of deal structures, including product in-licenses, research collaborations, co-development agreem [read more]

Phil Tinmouth

Vice President, Business Development & Alliance Management, Vertex Pharmaceuticals Incorporated

Mr. Tinmouth joined Vertex Pharmaceuticals as Director of Corporate Development in 2002 and has since been promoted to Vice President, Business Development & Alliance Management. His role at Vertex involves managing a group of professionals that source and execute licensing transactions and manage the various research and development alliances. Mr. Tinmouth has also had significant [read more]

10:00 Panel: In The Spotlight: Drug Development In Rare Diseases

Robin Jackman, President and CEO, Zacharon Pharmaceuticals
Deanna Petersen, Vice President Business Development, Shire HGT
Jeremy Springhorn, VP Corporate Strategy and Business Development, Alexion Pharmaceuticals, Inc.

We've seen an increased focus in the rare disease sector from large drug companies, the FDA and the NIH. This session will examine recent deal activities as well as the opportunities for and obstacles in developing drugs and medical devices for treating rare diseases.

Robin Jackman

President and CEO, Zacharon Pharmaceuticals

Robin Jackman is President and CEO of Zacharon Pharmaceuticals, a company discovering and developing first-in-class small molecule drugs targeting glycan biosynthesis for the treatment of rare lysosomal storage diseases and cancer. Dr. Jackman has 18 years of experience in business development, finance, clinical development, and scientific research. During that time he led or participated in over [read more]

10386.006_bioNetworkWest_2011_deanna_petersen_final_pic

Deanna Petersen

Vice President Business Development, Shire HGT

Deanna Petersen joined Shire in 2009 as Vice President of Business Development for Shire Human Genetic Therapies (HGT). Deanna is a broadly skilled senior executive with 15 years of leadership experience in strategic planning and global business development. Deanna is a member of Shire HGT’s senior leadership team and is responsible for identifying, evaluating and negotiating business opportunitie [read more]

Jeremy Springhorn

VP Corporate Strategy and Business Development, Alexion Pharmaceuticals, Inc.

Dr. Jeremy P. Springhorn is Vice President of Corporate Strategy and Business Development at Alexion, where he is responsible for managing Corporate Strategy, Licensing, Business Development and Competitive Intelligence for the Company. He also chairs the company's Licensing committee.Dr. Springhorn was one of the original scientists at Alexion and played an integral role in the engineering and de [read more]

11:00 Refreshment Break & Networking Opportunity

Refreshment Break & Networking Opportunity

11:30 Panel: New Strategies In Academic/ Industry Collaborations

Zafrira Avnur, Ph.D., Global Academic Innovation Partnering, Roche
Sylvaine Cases, Ph.D., Director, External Innovation, Sanofi
Neena Kadaba, Ph.D., Director of Industry Alliances , QB3
Teri Melese, Associate Professor of Medicine and Director, Research Technologies and Alliances School of Medicine Dean's Office, UCSF
Neela Patel, Ph.D., Director, External Research, Abbott - Global Pharmaceutical Research and Development

Collaborating with academia is one of the various strategies pharmaceutical companies are using to bring innovation to the industry and build up their early stage development pipelines. This discussion will cover recent examples of academic/industry collaborations including the variations in size and scope, the unique challenges they face in balancing different cultures and an assessment of how well this partnering model is working.

Zafrira Avnur, Ph.D.

Global Academic Innovation Partnering, Roche

Zafrira Avnur, Ph.D., is Global Academic Innovation Partnering Head at Roche Partnering She holds a post doctorate (Cancer Biology) from Stanford University, and a Ph.D. from Weizmann Institute (cell Biology). She was based in Palo Alto, California, USA, from 1987 until 2006, in various positions in the Research and Development area at Roche. Amongst the positions she held are Distinguished Scient [read more]

Sylvaine Cases, Ph.D.

Director, External Innovation, Sanofi

Sylvaine is currently Director of External Innovation in the sanofi-aventis department of Prospective & Strategic Initiatives. In this position, she is responsible for various scouting and partnering activities with academic centers and biotech in the Bay Area as well as the Oregon and Washington states.Prior to joining sanofi-aventis, Sylvaine has been working for 16 years in the [read more]

Neena Kadaba, Ph.D.

Director of Industry Alliances , QB3

Neena S. Kadaba, Ph.D. is the Director of Industry Alliances at QB3 (the California Institute for Quantitative Biosciences), a state institute that accelerates the commercialization of innovations from UCSF, UC Berkeley and UC Santa Cruz. Her goal is to initiate collaborations between industry and faculty from these three campuses and to expand QB3’s pre-commercial funding programs. She manages QB [read more]

10386.006_bioNetworkWest_2011_terry_melese

Teri Melese

Associate Professor of Medicine and Director, Research Technologies and Alliances School of Medicine Dean's Office, UCSF

Teri Melese is an Adjunct Associate Professor in the Department of Medicine at the University of California, San Francisco, and is Director of Research Technologies and Alliances in the UCSF School of Medicine Dean’s Office. Before joining UCSF in 2001, she ran an independent research laboratory in yeast genetics and molecular biology at Columbia University from 1988-1997 and in 1997 left Columbia [read more]

Neela Patel, Ph.D.

Director, External Research, Abbott - Global Pharmaceutical Research and Development

Dr. Patel is Director, External Research for Abbott Laboratories with responsibility for identification and evaluation of discovery-stage collaboration and licensing opportunities in the Western US. In addition, Dr. Patel serves as the therapy area liaison for oncology, partnering with senior management to create the overall strategy for the pipeline, conducting pro-active sear [read more]

12:30 Case Study: Merck And Lycera Collaborate On Anti- Inflammatory Discovery Deal

Suzanne Miller Mandala, Ph.D., Senior Director, Franchise Licensing Integrator, External Scientific Affair, Merck
Julia Owens, Ph.D., SVP, Corporate Development & Strategy, Lycera Corporation

Case Study: Merck And Lycera Collaborate On Anti- Inflammatory Discovery Deal

10386.006_bioNetworkWest_2011_mandala_suzanne_014_fin_5x7

Suzanne Miller Mandala, Ph.D.

Senior Director, Franchise Licensing Integrator, External Scientific Affair, Merck

Suzanne Mandala received her BA degree from Swarthmore College (Pennsylvania) and her PhD from the University of California, Santa Cruz. She was a postdoctoral fellow in the Department of Human Genetics at Yale University. Suzanne joined Merck research biologist in 1989 in the Infectious Disease Department. She distinguished herself as an expert in sphingolipid biology as applied to the developmen [read more]

10386.006_bioNetworkWest_2011_julia_owens_final

Julia Owens, Ph.D.

SVP, Corporate Development & Strategy, Lycera Corporation

Dr. Julia C. Owens brings to Lycera extensive experience in establishing corporate partnerships, in-licensing transactions and strategic planning. Prior to joining Lycera in 2010, Dr. Owens served as head of business development at QuatRx Pharmaceuticals for six years. During this time, Dr. Owens led QuatRx’s partnering processes, which resulted in a licensing deal with Galderma Labs and most rece [read more]

1:00 Networking Lunch For All Conference Attendees Hosted By Intralinks

Networking Lunch For All Conference Attendees Hosted By Intralinks

2:15 Panel: Current Options For Venture Capital Backed Companies Given The Economic Climate

Gaurav Aggarwal, MD, Principal, Panorama Capital
Mark Barrett, Sr. Director, Business Development , Johnson & Johnson
John Hollway, Vice President, Business Development, Achaogen Inc
Michael O'Donnell, Partner, Morrison Foerster

Industry experts are predicting we'll see a rise in the number biotech IPO's for 2011 and continue to see M&A dominate as the principal exit pathway. In this session the investment community will outline the options for VC-backed life science companies including investments, M&A and licensing in this environment and discuss how the increased pressure on VCs to realize exits affects their

Gaurav Aggarwal, MD

Principal, Panorama Capital

Dr. Aggarwal is a Partner at Panorama Capital and focuses on life sciences investments. He currently serves on the board of directors of Alvine Pharmaceuticals, Hyperion Therapeutics and Nextwave Pharmaceuticals, and was previously on the board of directors at Flowcardia, PIramed and Microscience Investments Limited. Dr. Aggarwal was closely involved in the firm’s investments in Amarin Corporation [read more]

Mark Barrett

Sr. Director, Business Development , Johnson & Johnson

Mr. Barrett has 15+ years of experience in business development, corporate strategy, and research in pharmaceutical and biotech companies and research institutions. Since 2002, Mark has been a member of Janssen’s worldwide Pharmaceutical Business Development group with responsibility for leadership and execution of global transactions across therapeutic and technology areas including commercial an [read more]

John Hollway

Vice President, Business Development, Achaogen Inc

John manages Achaogen's business development, strategic marketing, and legal activities, including in particular its non-dilutive financing strategies and its relationships with government agencies. Prior to joining Achaogen, John was the Vice President of Operations, Strategy & Corporate Development, and Chief Privacy Officer for Acurian, Inc., a clinical services company. There h [read more]

Michael O'Donnell

Partner, Morrison Foerster

Michael O'Donnell is a partner in the firm’s Palo Alto office, specializing in corporate and securities law. He has more than 25 years of experience providing general corporate representation to biopharmaceutical and other life sciences companies. He offers particular expertise in venture capital financings, public offerings, mergers an [read more]

3:15 Panel: Considerations In Building A Sustainable Global Biotech Company

Jeff Brennan, Senior Vice President, Chief Business Officer, Targacept, Inc.
Juergen Lasowski, Executive Vice President of Corporate Development and Strategy, Onyx Pharmaceuticals, Inc.
Samantha Truex, Vice President, Business Development, Biogen Inc.

In today's Biotech environment, is it still possible for a small start-up biotech company to evolve into the next Celgene? This session will explore the core questions and pressure points involved in planning for that level of growth and continuity. These core questions include funding sources and investor expectations, when and what to partner, how and when to build and exit capabilities, communicating to investors and Wall Street, etc.

10386.006_bioNetworkWest_2011_jeff_brennan

Jeff Brennan

Senior Vice President, Chief Business Officer, Targacept, Inc.

Jeffrey P. Brennan joined Targacept in September, 2003, as Vice President of Business and Commercial Development. Mr. Brennan has more than 25 years of pharmaceutical industry experience, and has held Executive Management positions at : Sanofi-Synthelabo, Inc., from 1996-2003, and most recently at Targacept. Throughout his career, Mr. Brennan has demonstrated success in both strategic development [read more]

10386.006_bioNetworkWest_2011_juergen_lasowski

Juergen Lasowski

Executive Vice President of Corporate Development and Strategy, Onyx Pharmaceuticals, Inc.

Juergen Lasowski, Ph.D., executive vice president of corporate development and strategy, joined Onyx in May 2008 as senior vice president of corporate development. Recognizing the important role that corporate development has in shaping the company’s pipeline and strategic direction, Dr. Lasowski’s role was expanded to include corporate strategy in January 2011. While at Onyx, he has been the arch [read more]

Samantha Truex

Vice President, Business Development, Biogen Inc.

Samantha Truex is Vice President, Business Development at Biogen Idec. She has been with Biogen Idec since 2006 and is currently leading business development for Biogen Idec’s hemophilia/hematology areas. Prior to this role, Samantha managed Biogen Idec’s long-lasting Factor IX and Factor VIII programs and the associated alliance with Swedish Orphan Biovitrum. From 2006-2008, Samantha was responsi [read more]

3:45 Refreshment Break & Networking Opportunity

Refreshment Break & Networking Opportunity

4:15 Panel: Implications Of Patent Reform On The Biopharma Industry

Kerry Flynn, Vice President, Intellectual Property, Shire Pharmaceuticals
Gladys Monroy, Partner, Morrison Foerster
Paul Barker, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Legislators claim that reforming the nation's patent system will promote innovation and help the economy. Legislation is aimed at eliminating the backlog of unexamined patents. This session will address the key components of patent reform including the impacts of first to file, the debate over inequitable conduct and the costs and benefits for big pharma, big biotech and small biotech companies.

Kerry Flynn

Vice President, Intellectual Property, Shire Pharmaceuticals

Kerry Flynn is Vice President for Intellectual Property at Shire. She has over 20 years of experience in the Intellectual Property and Licensing field, and has recently earned the newly released designation of Certified Licensing Professional from the Licensing Executives Society. Ms. Flynn was previously Vice President of Business Development and Intellectual Property at Transkaryotic Therapies, [read more]

Gladys Monroy

Partner, Morrison Foerster

Dr. Monroy is a partner in the Palo Alto office of Morrison & Foerster with a focus on patent law and biotechnology. She formerly served as co-chair of the firmwide Patent group as well as co-chair of the Life Sciences practice.

Dr. Monroy’s practice includes strategic counseling and comprehensive patent portfolio management for small, [read more]

Paul Barker

Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Paul Barker is a partner in Finnegan’s Palo Alto, California office. For more than 20 years, Mr. Barker has practiced patent law, with a particular focus in the fields of biotechnology and pharmaceuticals. In his patent prosecution practice, he prepares applications and responses to office actions, represents clients in reexamination and reissue proceedings, and prepares briefs to the appeal board [read more]

5:15 Cocktail Reception For All Attendees

Cocktail Reception For All Attendees






	Interested In Sponsoring?
	Send me email updates






	Interested In Sponsoring?
	Send me email updates

Conference Day Three

Kiva Kolstein Vice President, Head of Corporate New Business Development, Gerson Lehrman Group (GLG)

Doug Lichtman Professor of Law, UCLA and Counsel Member, Gerson Lehrman Group (GLG)

Steven Ertel Senior Vice President Corporate Developmemt, Acceleron Pharma Inc

Paul Eynott, Ph.D. Partnering & Innovation, US Head, Sanofi

James Schaeffer Executive Director, Worldwide Licensing and External Research, MERCK

Alexander Schuth Associate Director Business Development, Genentech, Inc.

Phil Tinmouth Vice President, Business Development & Alliance Management, Vertex Pharmaceuticals Incorporated

Robin Jackman President and CEO, Zacharon Pharmaceuticals

Deanna Petersen Vice President Business Development, Shire HGT

Jeremy Springhorn VP Corporate Strategy and Business Development, Alexion Pharmaceuticals, Inc.

Zafrira Avnur, Ph.D. Global Academic Innovation Partnering, Roche

Sylvaine Cases, Ph.D. Director, External Innovation, Sanofi

Neena Kadaba, Ph.D. Director of Industry Alliances , QB3

Teri Melese Associate Professor of Medicine and Director, Research Technologies and Alliances School of Medicine Dean's Office, UCSF

Neela Patel, Ph.D. Director, External Research, Abbott - Global Pharmaceutical Research and Development

Suzanne Miller Mandala, Ph.D. Senior Director, Franchise Licensing Integrator, External Scientific Affair, Merck

Julia Owens, Ph.D. SVP, Corporate Development & Strategy, Lycera Corporation

Gaurav Aggarwal, MD Principal, Panorama Capital

Mark Barrett Sr. Director, Business Development , Johnson & Johnson

John Hollway Vice President, Business Development, Achaogen Inc

Michael O'Donnell Partner, Morrison Foerster

Jeff Brennan Senior Vice President, Chief Business Officer, Targacept, Inc.

Juergen Lasowski Executive Vice President of Corporate Development and Strategy, Onyx Pharmaceuticals, Inc.

Samantha Truex Vice President, Business Development, Biogen Inc.

Kerry Flynn Vice President, Intellectual Property, Shire Pharmaceuticals

Gladys Monroy Partner, Morrison Foerster

Paul Barker Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP